SunTrust Upgrades Sarepta Therapeutic (SRPT) to Neutral
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
SunTrust Robinson Humphrey upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Reduce to Neutral with a price target of $48.00 (from $4.00).
Shares of Sarepta Therapeutic closed at $28.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Raises Price Target on Citizens Financial Group (CFG) Following 3Q EPS Beat
- Amazon (AMZN) PT Raised to $1050 at Goldman Sachs Into Q3 Print
- Credit Suisse Downgrades Time Warner (TWX) to Neutral Following Takeover
Create E-mail Alert Related CategoriesAnalyst PT Change, Upgrades
Related EntitiesSunTrust Robinson Humphrey
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!